APYX vs EOLS
APYX: Apyx Medical provides advanced helium plasma-based surgical technology for cosmetic body contouring and hospital-based electrosurgical procedures. EOLS: A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market.
Side-by-side fundamentals
| Metric | APYX | EOLS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.91 | $5.89 | |
| Market cap as of 2026-07-23 | $163M | $379M | |
| Net margin as of 2026-07-23 | -16.4% | -14.4% | EOLS higher |
| Gross margin as of 2026-07-23 | +63.1% | +66.1% | EOLS higher |
| Operating margin as of 2026-07-23 | -7.7% | -8.1% | APYX higher |
| ROE as of 2026-07-23 | -90.6% | -410.2% | APYX higher |
| ROA as of 2026-07-23 | -14.9% | -19.4% | APYX higher |
| Debt / equity as of 2026-07-23 | 2.74 | 22.00 | APYX lower |
| Revenue growth (YoY) as of 2026-07-23 | +18.2% | +9.6% | APYX higher |
| Revenue CAGR (3y) SEC XBRL | +5.9% | +26.0% | EOLS higher |
| Beta as of 2026-07-23 | 1.40 | 1.39 | |
| 1-year return as of 2026-07-22 close | +73.8% | -37.0% | APYX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.